Proxy Votes Now

Home › Activist investors › Mangless Daniel John

Mangless Daniel John

Dissident not on the roster. Positions and campaigns from Mangless Daniel John’s SEC filings. Updated November 20, 2026.

Filer entities
Mangless Daniel John
SEC CIK
1779475 (Mangless Daniel John)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
0current positions
0new or changed in 90 days
0active campaigns
1campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (0)

No current position by this definition.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (1)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Zevra Therapeutics, Inc.Board seats Contested vote held — 0 of 1 of the activist's nominees elected May 29, 2025 Mar 3, 2023 Proxy contest filed latest (11) how managers voted

How large managers voted in Mangless Daniel John’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

Contested director elections at which Mangless Daniel John had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.

Top 20 managers across 1 contest

ManagerBacked the activistZevra Therapeutic…
2025
Vanguard0 of 1 (0%) Company
BlackRock0 of 1 (0%) Company
Fidelity0 of 1 (0%) Company
Charles Schwab0 of 1 (0%) Company
Pacific Life0 of 1 (0%) Company
Equitable0 of 1 (0%) Company
TIAA0 of 1 (0%) Company
QUANTITATIVE MASTER SERIES LLC0 of 1 (0%) Company
Lincoln Financial0 of 1 (0%) Company
State Street0 of 1 (0%) Company
Global X0 of 1 (0%) Company
AIG/SunAmerica0 of 1 (0%) Company
Northern Trust0 of 1 (0%) Company
ProShares0 of 1 (0%) Company
John Hancock0 of 1 (0%) Company
Bridge Builder Trust0 of 1 (0%) Company
Brighthouse0 of 1 (0%) Split
SEI0 of 1 (0%) Company
Nationwide0 of 1 (0%) Company
Guardian Variable Products Trust0 of 1 (0%) Company

— = no N-PX votes on the contested director elections found for that manager.

Zevra Therapeutics, Inc. · meeting May 29, 2025 · 0 of 1 of the activist’s nominees elected

Result: Form 8-K, Item 5.07. Activist’s nominees: Arthur C. Regan (not elected (8-k tally)). Company’s nominees: Wendy Dixon, Ph.D. (elected (8-k tally)); Tamara A. Favorito (elected (8-k tally)).

ManagerStanceFOR the activist’s nomineesAvg. shares FOR each activist nomineeFOR the company’s nominees
Vanguard Backed the company's nominees 0 of 9 fund votes 0 18 of 18 fund votes
BlackRock Backed the company's nominees 0 of 11 fund votes 0 22 of 22 fund votes
Fidelity Backed the company's nominees 0 of 19 fund votes 0 38 of 38 fund votes
Charles Schwab Backed the company's nominees 0 of 2 fund votes 0 4 of 4 fund votes
Pacific Life Backed the company's nominees 0 of 5 fund votes 0 10 of 10 fund votes
Equitable Backed the company's nominees 0 of 8 fund votes 0 16 of 16 fund votes
TIAA Backed the company's nominees 0 of 5 fund votes 0 10 of 10 fund votes
QUANTITATIVE MASTER SERIES LLC Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Lincoln Financial Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
State Street Backed the company's nominees 0 of 4 fund votes 0 8 of 8 fund votes
Global X Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
AIG/SunAmerica Backed the company's nominees 0 of 2 fund votes 0 4 of 4 fund votes
Northern Trust Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
ProShares Backed the company's nominees 0 of 11 fund votes 0 22 of 22 fund votes
John Hancock Backed the company's nominees 0 of 3 fund votes 0 6 of 6 fund votes
Bridge Builder Trust Backed the company's nominees 0 of 2 fund votes 0 4 of 4 fund votes
Brighthouse Split 0 of 2 fund votes 0 2 of 4 fund votes
SEI Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Nationwide Backed the company's nominees 0 of 2 fund votes 0 4 of 4 fund votes
Guardian Variable Products Trust Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
DWS Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Goldman Sachs Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Victory Capital Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Voya Backed the company's nominees 0 of 2 fund votes 0 4 of 4 fund votes
Direxion Shares ETF Trust Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
T. Rowe Price Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
AQR Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Calvert Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Dimensional Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Columbia Threadneedle Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
PENN SERIES FUNDS INC Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Brinker Capital Destinations Trust Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes
Guggenheim Backed the company's nominees 0 of 4 fund votes 0 8 of 8 fund votes
Advisors' Inner Circle Fund III Backed the company's nominees 0 of 1 fund votes 0 2 of 2 fund votes

Source: N-PX reports filed by 34 managers for the meeting of May 29, 2025; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Contest vote: nominees not elected
Outcome of each campaign (1)
CompanyOutcomeDetailDateFirst filing
Zevra Therapeutics, Inc. Contest vote: nominees not elected 0 of 1 of the activist's nominees elected May 29, 2025 Mar 3, 2023

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.